Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Medical devices company Tissue Regenix said its OrthoPure XT tissue regeneration product had obtained a CE Mark.
The mark has been awarded for revision of the anterior cruciate ligament following re-rupture and additionally, permitted use for the reconstruction of other knee ligaments.
OrthoPure XT was a decellularised xenograft ligament that enabled tissue regeneration, utilising the company patented dCELL technology, which originated from the University of Leeds.
At 8:49am: (LON:TRX) Tissue Regenix Group PLC share price was +0.05p at 0.43p